Go Pro
NASDAQ:SION

Sionna Therapeutics Q3 2025 Earnings Report

Sionna Therapeutics logo
$5.51 -0.51 (-8.47%)
Closing price 04:00 PM Eastern
Extended Trading
$5.49 -0.02 (-0.29%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sionna Therapeutics EPS Results

Actual EPS
-$0.46
Consensus EPS
-$0.52
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Sionna Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sionna Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 5, 2025
Conference Call Time
7:00AM ET

Sionna Therapeutics Earnings Headlines

Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
See More Sionna Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sionna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sionna Therapeutics and other key companies, straight to your email.

About Sionna Therapeutics

Sionna Therapeutics (NASDAQ:SION) is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disease that affects the lungs and other organs. The company is developing small-molecule therapies designed to address defects in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is responsible for transporting salt and fluids across cell membranes.

Sionna’s research is centered on nucleotide-binding domain 1 (NBD1) correctors. These investigational medicines are intended to stabilize and improve the function of defective CFTR proteins, including proteins affected by the common F508del mutation. The company’s approach is designed to potentially form part of combination therapies that target multiple stages of CFTR production, processing and activity.

Sionna’s pipeline includes preclinical and clinical-stage programs evaluating the safety, tolerability and pharmacological activity of its CFTR modulators. The company’s goal is to develop oral treatments that may benefit a broad population of people with cystic fibrosis, including patients who have limited treatment options because of the specific mutations they carry.

View Sionna Therapeutics Profile